Pilot study of FOLFOX/FOLFIRI for locally advanced and metastatic pancreatic cancer
- Conditions
- locally advanced and metastatic pancreatic cancer
- Registration Number
- JPRN-UMIN000014079
- Lead Sponsor
- Osaka Medical College Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
1) with pulmonary fibrosis or interstitial pneumonia which can be detected from X-ray incontrovertibly or has clinical symptom 2) with severe diarrhea within 3 days before entry 3) with other severe diseases (heart failure, renal disfunction, liver disfunction, intestinal paralysis, ileus, uncontrolled DM) 4) patients whom administered Flucitosine or Fenitoin or Warfarin 5) with active double cancers whose disease free period is shorter than 5 years, Carcinoma in situ can be excluded. 6) with infectious disease which needs therapy 7) with body temperature over 38 degrees Celsius 8) women who are pregnant or expect to be pregnant, or nursing female 9) patients whom doctor in chief decides not to register to this study due to psychological disease or symptoms 10) general administration of steroids 11) with indication of FOLFIRINOX therapy 12) in the case of receiving adjuvant chemotherapy, recurrence within 180 days from the last administration of adjuvant chemotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method